We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




DNA Test Accurately Predicts Resistance to Common Chemotherapy Treatments

By LabMedica International staff writers
Posted on 24 Jun 2025

Chemotherapy remains a cornerstone of cancer treatment, but its toxicity to healthy cells can result in severe short- and long-term side effects. More...

Despite its widespread use, not all patients respond to chemotherapy, leading to unnecessary exposure to its harsh effects. Addressing this challenge, researchers have developed a new test that can accurately predict whether a tumor will be resistant to common chemotherapy treatments, offering a path toward more personalized and effective cancer care.

The predictive test, created by scientists at the Cancer Research UK Cambridge Institute (Cambridge, UK), in collaboration with other researchers, aims to improve treatment decision-making by identifying, in advance, which patients are unlikely to benefit from certain chemotherapy regimens. The test works by analyzing chromosomal instability (CIN) signatures—specific changes in the order, structure, and number of copies of DNA in cancer cells. By sequencing the full genome of a tumor and comparing it to that of healthy cells, the researchers can detect patterns of chromosomal disruption that are indicative of chemotherapy resistance. These patterns help predict resistance to three major classes of chemotherapy: platinum-based, anthracycline, and taxane.

To validate the test, researchers applied it to data from 840 patients with various types of cancer. Patients were classified as either “chemotherapy resistant” or “chemotherapy sensitive,” and were then virtually assigned to an alternative chemotherapy type to assess how long treatment remained effective. This simulation, which emulated a randomized controlled trial, showed that predicted resistance was strongly associated with treatment failure. For example, resistance to taxane chemotherapy corresponded with higher failure rates in ovarian, metastatic breast, and metastatic prostate cancers. Similarly, the study published in Nature Genetics, shows that resistance to anthracycline chemotherapy predicted worse outcomes in ovarian and metastatic breast cancer, while resistance to platinum-based chemotherapy was linked to higher failure rates in ovarian cancer.

The test is still undergoing further analysis and holds significant clinical promise. By identifying the likelihood of treatment resistance at the time of diagnosis, physicians could spare patients from ineffective chemotherapy and its associated side effects. The team behind the test is now preparing regulatory submissions for clinical use and is working on expanding the technology to include predictions for other targeted cancer drugs across a broader range of cancer types.

“It was important to us to create a test that could be easily adopted in clinic, using material we already collect during diagnosis and well-established genomic sequencing methods,” said Dr. Ania Piskorz, co-lead author and Head of Genomics at Cancer Research UK Cambridge Institute. “The test is based on the full DNA sequence that we get from these methods, and we can adapt it to work alongside other genomic sequencing methods that are commonly used to personalize treatment for cancer.”

Related Links:
Cancer Research UK Cambridge Institute


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Test Reader
DIA5000
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: A saliva test can help predict future metabolic health concerns including diabetes and obesity (Photo courtesy of 123RF)

Saliva Test to Enable Early Detection of Diabetes and Obesity

Type 2 diabetes affects about 400 million people globally and is typically diagnosed through elevated blood glucose levels. However, conditions like insulin resistance and hyperinsulinemia may begin developing... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.